EyePoint Pharmaceuticals, Inc. — Director's Dealing 2026

Jan 7, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EyePoint, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2026-01-06

Reporting Person: Duker Jay S. (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2026-01-06	Common Stock	M	20793.00	$0.00	Acquired	87806.00	Direct
2026-01-06	Common Stock	F	10054.00	$16.86	Disposed	77752.00	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2026-01-06	Restricted Stock Units	$0.00	M	20793.00	Disposed		Common Stock (20793.00)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	99165.00	Indirect

Footnotes

F1: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units.

F2: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

F3: The restricted stock units vest in three ratable annual installments beginning January 6, 2024.